PTCT vs XOMA
PTCT: PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved products and partnered collaboration deals. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | PTCT | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $78.40 | $40.17 | |
| Market cap as of 2026-07-23 | $6.5B | $710M | |
| P/E as of 2026-07-23 | 881.48 | 21.00 | XOMA lower |
| PEG as of 2026-07-23 | 1.20 | n/a | |
| Net margin as of 2026-07-23 | +0.9% | +69.6% | XOMA higher |
| Gross margin as of 2026-07-23 | +32.6% | +100.0% | XOMA higher |
| Operating margin as of 2026-07-23 | +8.9% | +61.3% | XOMA higher |
| ROE as of 2026-07-23 | +0.1% | +32.4% | XOMA higher |
| ROA as of 2026-07-23 | +0.3% | +13.1% | XOMA higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.91 | PTCT lower |
| Revenue growth (YoY) as of 2026-07-23 | -53.3% | +13.2% | XOMA higher |
| Revenue CAGR (3y) SEC XBRL | +35.3% | +105.3% | XOMA higher |
| Dividend yield as of 2026-07-23 | n/a | +0.8% | |
| Beta as of 2026-07-23 | 0.54 | 0.88 | |
| 1-year return as of 2026-07-22 close | +69.0% | +48.0% | PTCT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.